^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    13d
    ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2028 | Trial completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • evorpacept (ALX148)
    15d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2027 --> Nov 2033 | Trial primary completion date: Mar 2027 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    16d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    17d
    BEST-NMOSD: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD (clinicaltrials.gov)
    P4, N=540, Not yet recruiting, Massachusetts General Hospital | N=160 --> 540
    Enrollment change
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Uplizna (inebilizumab-cdon)
    20d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    20d
    Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, Gottfried von Keudell, MD PhD | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Oct 2031 | Trial primary completion date: Feb 2027 --> Oct 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    21d
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=422, Suspended, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    28d
    Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=349, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    28d
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1m
    Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cisplatin • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    1m
    CD2 SCD: Siplizumab for Sickle Cell Disease Transplant (clinicaltrials.gov)
    P1/2, N=1, Terminated, Columbia University | N=18 --> 1 | Trial completion date: Jul 2029 --> Dec 2025 | Recruiting --> Terminated; Closed by the industry collaborator
    Enrollment change • Trial completion date • Trial termination
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • sirolimus • Truxima (rituximab-abbs)
    1m
    Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=81, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)